Target Price | GBP136.04 |
Price | GBP116.00 |
Potential | 17.27% |
Number of Estimates | 25 |
25 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP136.04. This is 17.27% higher than the current stock price. The highest price target is GBP179.71 54.92% , the lowest is GBP104.83 9.63% . | |
A rating was issued by 33 analysts: 27 Analysts recommend AstraZeneca to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 17.27% . Most analysts recommend the AstraZeneca stock at Purchase. |
25 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP45.8b . This is 8.27% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP47.9b 13.26% , the lowest is GBP43.1b 1.76% .
This results in the following potential growth metrics:
2024 | GBP42.3b | 14.82% |
---|---|---|
2025 | GBP45.8b | 8.25% |
2026 | GBP48.8b | 6.50% |
2027 | GBP51.4b | 5.45% |
2028 | GBP54.3b | 5.58% |
2029 | GBP57.3b | 5.47% |
18 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP16.2b . This is 17.66% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP19.2b 39.22% , the lowest is GBP14.0b 1.50% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | GBP13.8b | 19.32% |
---|---|---|
2025 | GBP16.2b | 17.63% |
2026 | GBP17.8b | 10.07% |
2027 | GBP19.8b | 10.79% |
2028 | GBP20.2b | 2.06% |
2029 | GBP23.8b | 18.15% |
2024 | 32.54% | 3.91% |
---|---|---|
2025 | 35.36% | 8.67% |
2026 | 36.54% | 3.34% |
2027 | 38.39% | 5.06% |
2028 | 37.11% | 3.33% |
2029 | 41.57% | 12.02% |
17 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is GBP5.27 . This is 48.03% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is GBP6.09 71.07% , the lowest is GBP3.31 7.02% .
This results in the following potential growth metrics and future valuations:
2024 | GBP3.55 | 14.89% |
---|---|---|
2025 | GBP5.27 | 48.45% |
2026 | GBP6.24 | 18.41% |
2027 | GBP6.99 | 12.02% |
2028 | GBP8.03 | 14.88% |
2029 | GBP9.29 | 15.69% |
Current | 32.59 | 2.75% |
---|---|---|
2025 | 22.03 | 32.40% |
2026 | 18.58 | 15.66% |
2027 | 16.59 | 10.71% |
2028 | 14.44 | 12.96% |
2029 | 12.49 | 13.50% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.36 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.93 .
This results in the following potential growth metrics and future valuations:
Current | 4.72 | 3.67% |
---|---|---|
2025 | 4.36 | 7.68% |
2026 | 4.09 | 6.11% |
2027 | 3.88 | 5.17% |
2028 | 3.67 | 5.29% |
2029 | 3.48 | 5.18% |
Current | 4.25 | 2.83% |
---|---|---|
2025 | 3.93 | 7.64% |
2026 | 3.69 | 6.11% |
2027 | 3.50 | 5.17% |
2028 | 3.31 | 5.29% |
2029 | 3.14 | 5.18% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.